What were the key takeaways from Biorestorative's earnings call?

What were the key takeaways from Biorestorative’s earnings call?

What factors drove the changes in Biorestorative's revenue and profit?

What is Biorestorative's gross profit margin?

What is the revenue and EPS growth rate for Biorestorative year over year?

Did Biorestorative beat or miss consensus estimates last quarter?

What is Biorestorative's latest dividend and current dividend yield?

What guidance did Biorestorative's management provide for the next earnings period?

- **Market Expansion Focus**: $63B BioCosmeceuticals opportunity with customizable exosome therapies; direct-to-professional and DTC strategies.
- **Clinical Milestone**: Phase II BRTX-100 enrollment nearing completion; FDA Type B meeting in December for potential accelerated BLA.
- **Financial Strength**: $5.6M cash post-financing; managing losses while investing in growth initiatives.
- **IP Expansion**: Japanese patent for ThermoStem allogeneic stem cell therapy; licensing discussions ongoing.
- **Resource Allocation**: Prioritizing lumbar spine trial; cervical trial on hold for now.


**【CEO Summary Section】**
- Emphasized dual focus on clinical development and commercial growth, highlighting the $63 billion BioCosmeceuticals market opportunity.
- BioCosmeceuticals revenue strategy includes exclusive distribution, direct-to-professional sales, and potential DTC products, leveraging customizable exosome-based therapies.
- Phase II BRTX-100 trial nearing enrollment completion (over 3/4 of 99 patients enrolled), with blinded data to remain until FDA Type B meeting in December.
- Recent $1.1 million financing strengthens cash position to $5.6 million, supporting clinical and commercial milestones.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $11.8 million (royalty-only), down 95% YoY from $233.6 million due to delayed BioCosmeceutical orders.
- Net loss: $3 million ($0.33/share) vs. $1 million ($0.13/share) in Q3 2024, driven by higher R&D and G&A expenses.
- Cash reserves: $4.5 million + $1.1 million from recent financing, no debt.

**【VP R&D Update】**
- BRTX-100 Phase II trial targeting chronic lumbar disc disease, with Fast Track designation enabling accelerated BLA discussions.
- ThermoStem program for obesity: IP expansion with Japanese patent covering allogeneic stem cell therapy and delivery methods.
- Ongoing licensing discussions with a commercial-stage regenerative medicine company.

**【Q&A Highlights】**
- BioCosmeceuticals strategy: Three-pronged approach (exclusive distribution, direct sales, DTC) to maximize margins and market penetration.
- FDA Type B meeting expected in December to discuss single Phase III pathway, potentially shaving 3 years off development timeline.
- Cervical spine trial on hold due to resource prioritization, but protocol approved for future expansion.
- Q4 BioCosmeuticals revenue uncertain but optimistic for scaling in 2026+ with Crystal Romano's leadership.


BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript

- **Revenue Soars 240%**: BioCosmeceuticals contract manufacturing drives $303,000 Q2 revenue.
- **BRTX-100 Trial Success**: 74% of patients achieve >50% ODI improvement, 72% VAS reduction.
- **Strong Cash Position**: $7.4 million liquidity with no debt.
- **FDA Regulatory Momentum**: Type B meeting planned to accelerate BLA timeline.
- **Cost Efficiency**: SG&A expenses expected to decline 20-30% in second half.

**【CEO Summary Section】**
- Q2 2025 marked strong execution across all business areas, building on Q1 momentum.
- Highlighted progress in Phase II BRTX-100 trial for CLDD with >74% of subjects showing >50% improvement in Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) at 52 weeks.
- Enrolled over 75% of 99-subject target, with no serious adverse events reported.
- Planning FDA Type B meeting to discuss accelerated regulatory pathway for BLA submission.
- Ended Q2 with $7.4 million in cash, no debt, and strong financial position to support strategic initiatives.

**【CFO Financial Commentary】**
- Q2 2025 revenue surged 240% YoY to $303,000, driven by BioCosmeuticals contract manufacturing.
- Net loss narrowed to $2.7 million ($0.30/share) vs. $4 million ($0.50/share) in Q2 2024.
- Operating expenses reduced through improved manufacturing efficiency and vendor pricing.
- Projected SG&A expenses to trend lower in Q3-Q4 2025 as enrollment slows ahead of Phase III.

**【R&D Update】**
- BRTX-100 Phase II trial demonstrating >70% responder rate for both pain and function metrics.
- ThermoStem metabolic program advancing with comprehensive patent portfolio and active licensing discussions.
- FDA Fast Track designation maintained with strong safety profile.

**【Q&A Highlights】**
- Focused on completing CLDD trial before exploring cervical spine indications.
- BioCosmeceuticals revenue growth expected to continue, though quarterly variability possible.
- COGS optimized through process improvements, maintaining high-margin business model.
- FDA supportive of cell therapy innovation, with potential for interim analysis after Type B meeting.

BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: 28% YoY driven by European BRTX-200 launch.
- **AI Investment Payoff**: $50M bet on AI drug discovery to accelerate pipeline.
- **Key Regulatory Milestones**: BRTX-100 FDA feedback Q2, Phase 3 enrollment 80% complete.
- **Cash Position Strong**: $125M cash with 2+ years runway; 2025 FCF breakeven target.
- **APAC Expansion Surge**: Japan partnership drives 500% YoY revenue growth.


**【Management Opening Remarks】**
- CEO highlighted Q1 2025 as a transformative quarter with significant progress in pipeline development and strategic partnerships.
- Emphasized focus on operational efficiency and capital allocation to drive long-term growth.
- Noted regulatory updates for lead product BRTX-100, with FDA feedback expected in Q2.

**【CEO Commentary】**
- Reported 28% YoY revenue growth driven by commercial launch of BRTX-200 in Europe.
- Announced $50M strategic investment in AI-driven drug discovery platform.
- Highlighted pipeline expansion with 3 new IND filings in Q1.
- Reiterated 2025 guidance of $200-220M revenue, +20% YoY.

**【CFO Financial Commentary】**
- GAAP net loss narrowed to $0.15M vs. $1.2M prior year, driven by 12% OpEx decline.
- Cash balance of $125M provides >2 years of runway at current burn rate.
- Non-GAAP R&D spend of $18.5M reflects prioritization of lead assets.
- Projected 2025 FCF breakeven with BRTX-100 launch in H2.

**【Q&A Highlights】**
- **Pipeline Timing**: BRTX-100 Phase 3 enrollment 80% complete; BRTX-300 Phase 1b data expected Q3.
- **Partnerships**: New collaboration with European biotech for stem cell therapies.
- **Regulatory Risk**: FDA requesting additional tox data for BRTX-300; company confident in Q4 submission.
- **Market Expansion**: Japan partnership for BRTX-200; APAC revenue +500% YoY.


BioRestorative Therapies (BRTX)-14 May 25-2025 Q1 Earnings call transcript

- **Phase II Data Breakthrough**: 70% of patients achieved >30% pain/function improvement, with no safety concerns.
- **Financial Fortitude**: $13.1M cash reserve supports full enrollment and strategic flexibility.
- **FDA Pathway**: Exploring accelerated approval based on interim results, with pivotal trial potential.
- **Clinical Milestones**: 26-week unblinded analysis in early 2025, 52-week data in Q1 2025, and MRI remodeling data to follow.

**【CEO Opening Remarks】**
- Highlighted the Phase II BRTX-100 clinical trial results as the primary focus, emphasizing 70% of 10 patients achieving >30% improvement in pain and function at 26 weeks.
- Noted the product's ability to exceed FDA-defined 30% improvement thresholds, with some patients showing up to 90% improvement.
- Announced no severe adverse events or dose-limiting toxicities, with safety data supporting continued enrollment.
- Highlighted the company's strong financial position with $13.1 million in cash and no debt, enabling strategic flexibility.

**【CFO Financial Commentary】**
- Reported Q3 2024 cash balance of $13.1 million, with no outstanding debt.
- Emphasized financial stability and ability to fund ongoing clinical trials without immediate need for additional capital.

**【Q&A Key Highlights】**
- **Enrollment Progress**: Confirmed enrollment exceeds 10 patients, with full 99-patient enrollment expected by year-end 2024.
- **Data Timing**: Unblinded interim analysis at 26 weeks anticipated in early 2025, with plans to present expanded 52-week data in Q1 2025.
- **FDA Strategy**: Discussed potential for accelerated approval based on Phase II data, with consideration of pivotal trial design.
- **Placebo Effect**: Acknowledged saline injections showing temporary improvement, but BRTX-100 demonstrating sustained therapeutic effects.
- **Radiographic Endpoints**: Teased future MRI data to demonstrate disc remodeling, complementing patient-reported outcomes.
- **Market Opportunity**: Highlighted the $100+ billion musculoskeletal market and BRTX-100's potential to address unmet needs in chronic disc disease.

Actual	-4.99	-1.28	-1.28	-0.77	-0.64	-0.6	-0.33	-0.5	-0.13	-0.2	-0.64	-0.3	-0.33
Forecast	-4.99	-0.55	-1.45	-0.795	-0.68	-0.69	-0.52	-0.57	-0.4333	-0.3433	-0.325	-0.37	-0.36
Surprise	0.00%	-132.73%	+11.72%	+3.14%	+5.88%	+13.04%	+36.54%	+12.28%	+70.00%	+41.74%	-96.92%	+18.92%	+8.33%

BRTX

BRTX fundamentals

BRTX Q3 2025 Earnings

Earnings Call

You can ask Aime

BRTX

BRTX fundamentals

BRTX Q3 2025 Earnings

Earnings Call

BRTX Earnings Call Summary for Q3/20254:30 PM on Nov 12, 2025

BRTX Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

BRTX Earnings Call Summary for Q1/20254:30 PM on May 14, 2025

BRTX Earnings Call Summary for Q4/2024 Mar 27, 2026

BRTX Earnings Call Summary for Q3/20244:30 PM on Nov 13, 2024

You can ask Aime